全文获取类型
收费全文 | 211篇 |
免费 | 20篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 2篇 |
基础医学 | 24篇 |
口腔科学 | 1篇 |
临床医学 | 25篇 |
内科学 | 39篇 |
神经病学 | 18篇 |
特种医学 | 16篇 |
外科学 | 17篇 |
综合类 | 2篇 |
预防医学 | 77篇 |
眼科学 | 1篇 |
药学 | 4篇 |
出版年
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2020年 | 4篇 |
2019年 | 4篇 |
2018年 | 8篇 |
2017年 | 9篇 |
2016年 | 9篇 |
2015年 | 5篇 |
2014年 | 11篇 |
2013年 | 19篇 |
2012年 | 17篇 |
2011年 | 25篇 |
2010年 | 10篇 |
2009年 | 12篇 |
2008年 | 16篇 |
2007年 | 4篇 |
2006年 | 9篇 |
2005年 | 10篇 |
2004年 | 5篇 |
2003年 | 13篇 |
2002年 | 4篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1986年 | 3篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有231条查询结果,搜索用时 46 毫秒
231.
Matthias Blüher MD Mohini Aras MD Louis J. Aronne MD Rachel L. Batterham MD Francesco Giorgino MD Linong Ji MD Kirsi H. Pietiläinen MD Oliver Schnell MD Elena Tonchevska MSc John P.H. Wilding MD 《Diabetes, obesity & metabolism》2023,25(8):2058-2072
Obesity is a chronic, progressive and relapsing disease with a rising global prevalence associated with increased morbidity and mortality and reduced quality of life. Treatment of obesity requires a comprehensive medical approach that includes behavioural interventions, pharmacotherapy and bariatric surgery. The degree of weight loss with all approaches is highly heterogeneous, and long-term weight maintenance remains challenging. For years, antiobesity medications have been limited in number, often delivering meagre efficacy and raising numerous safety concerns. Therefore, there is a need for the development of highly efficacious and safe new agents. Recent insights into the complex pathophysiology of obesity have increased our understanding of intervenable targets for pharmacotherapies to treat obesity and improve weight-related cardiometabolic complications, namely, type 2 diabetes, hyperlipidaemia and hypertension. As a result, novel potent therapies have emerged, such as semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) recently approved for the treatment of obesity. Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity. Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA, has recently demonstrated that body weight reduction exceeding 20% in people with obesity and coupled with improved cardiometabolic measures is feasible. Thus, these novel agents promise to narrow the gap between the weight-loss effects of behaviour interventions, previous pharmacotherapies, and bariatric surgery. In this narrative review, we highlight established and emerging therapeutic treatments for long-term obesity management and position them in a framework according to their weight loss effects. 相似文献